1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. Recordati
  6. News
  7. Summary
    REC   IT0003828271

RECORDATI

(REC)
  Report
Delayed Borsa Italiana  -  11:35 2022-06-24 am EDT
41.86 EUR   +7.64%
06/20RECORDATI : Share buy-back program to service the stock option plans
PU
06/14RECORDATI : Ultima presentazione del gruppo
PU
06/14RECORDATI : Latest Company presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Recordati Industria Chimica e Farmaceutica S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2022

05/10/2022 | 12:02pm EDT

Recordati Industria Chimica e Farmaceutica S.p.A. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was EUR 419.38 million compared to EUR 384.84 million a year ago. Net income was EUR 96.72 million compared to EUR 89.87 million a year ago. Basic earnings per share from continuing operations was EUR 0.47 compared to EUR 0.436 a year ago. Diluted earnings per share from continuing operations was EUR 0.462 compared to EUR 0.43 a year ago.


© S&P Capital IQ 2022
All news about RECORDATI
06/20RECORDATI : Share buy-back program to service the stock option plans
PU
06/14RECORDATI : Ultima presentazione del gruppo
PU
06/14RECORDATI : Latest Company presentation
PU
05/23RECORDATI : Ex-dividend day for final dividend
FA
05/18Alliance Pharma Chair to Step Down in 2023; Successor Named
MT
05/10Recordati Industria Chimica e Farmaceutica S.p.A. Reports Earnings Results for the Firs..
CI
05/10Recordati Industria Chimica Seeks M&A
CI
05/10TRANSCRIPT : Recordati Industria Chimica e Farmaceutica S.p.A., Q1 2022 Earnings Call, May..
CI
05/10Recordati Confirms 2022 Financial Targets
MT
05/10Recordati confirms 2022 targets despite Ukraine conflict
RE
More news
Analyst Recommendations on RECORDATI
More recommendations
Financials
Sales 2022 1 755 M 1 852 M 1 852 M
Net income 2022 383 M 404 M 404 M
Net Debt 2022 1 366 M 1 441 M 1 441 M
P/E ratio 2022 23,6x
Yield 2022 2,67%
Capitalization 8 606 M 9 078 M 9 078 M
EV / Sales 2022 5,68x
EV / Sales 2023 5,16x
Nbr of Employees 4 303
Free-Float 46,5%
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 41,86 €
Average target price 46,38 €
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Robert Koremans Chief Executive Officer
Luigi Felice la Corte Group Chief Financial Officer
Andrea Recordati Chairman
Raffaele Sabia Senior VP-Pharmaceutical Research & Development
Giovanni Minora Head-Group Audit & Compliance
Sector and Competitors
1st jan.Capi. (M$)
RECORDATI-25.91%9 078
JOHNSON & JOHNSON5.02%479 678
ELI LILLY AND COMPANY13.21%293 110
PFIZER, INC.-15.17%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202